In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $44.82, up 7.05% from its previous closing price of $41.87. In other words, the price has increased by $7.05 from its previous closing price. On the day, 1.45 million shares were traded. RNA stock price reached its highest trading level at $45.585 during the session, while it also had its lowest trading level at $41.12.
Ratios:
To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on September 24, 2024, initiated with a Buy rating and assigned the stock a target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.BofA Securities initiated its Buy rating on May 03, 2024, with a $40 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 21 ’24 when LEVIN ARTHUR A sold 5,000 shares for $46.63 per share. The transaction valued at 233,168 led to the insider holds 14,830 shares of the business.
ARTHUR A LEVIN bought 8,323 shares of RNA for $419,895 on Oct 21 ’24. On Oct 16 ’24, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 25,000 shares for $48.52 each. As a result, the insider received 1,213,010 and left with 94,018 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5298575360 and an Enterprise Value of 3630634496. For the stock, the TTM Price-to-Sale (P/S) ratio is 490.65 while its Price-to-Book (P/B) ratio in mrq is 4.01. Its current Enterprise Value per Revenue stands at 342.545 whereas that against EBITDA is -12.844.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $50.78, while it has fallen to a 52-week low of $5.04. The 50-Day Moving Average of the stock is 0.94%, while the 200-Day Moving Average is calculated to be 36.77%.
Shares Statistics:
It appears that RNA traded 1.30M shares on average per day over the past three months and 708360 shares per day over the past ten days. A total of 117.12M shares are outstanding, with a floating share count of 108.62M. Insiders hold about 7.26% of the company’s shares, while institutions hold 93.52% stake in the company. Shares short for RNA as of 1728950400 were 14884198 with a Short Ratio of 11.43, compared to 1726185600 on 11979442. Therefore, it implies a Short% of Shares Outstanding of 14884198 and a Short% of Float of 15.560001000000002.
